Research Project
Grant-in-Aid for Young Scientists (B)
Breast cancer is the most common cancer among women. Developments in the treatment of some types of breast cancer have increased the overall survival of patients. Tamoxifen that is an antagonist of the estrogen receptor and trastuzumab that is a monoclonal antibody that acts in the HER2 receptor have improved the survival outcome of luminal and Her2 breast cancer subtypes, respectively. However, triple negative breast cancer (TNBC) is currently the only major breast tumor subtype without effective targeted therapy and, as a consequence, usually presents a poor outcome. Because of poor prognosis and a more aggressive phenotype, there is an urgent clinical need to identify novel therapeutic targets for TNBCs. To identify new therapeutic targets in TNBC, we analyzed gene expression data of a cohort composed of 294 patients diagnosed with TNBC and identified Kallikrein-related-peptidase 3 (KLK3) as a biomarker for TNBC.
All 2016 2015 Other
All Int'l Joint Research (1 results) Journal Article (3 results) (of which Int'l Joint Research: 2 results, Peer Reviewed: 3 results, Open Access: 3 results, Acknowledgement Compliant: 2 results) Presentation (7 results) (of which Int'l Joint Research: 2 results, Invited: 2 results)
Cancer Research
Volume: 76 Issue: 4 Pages: 974-983
10.1158/0008-5472.can-15-2135
120005741610
Scientific Report
Volume: 5 Issue: 1 Pages: 12464-12464
10.1038/srep12464
Volume: 5 Issue: 1 Pages: 13076-13076
10.1038/srep13076
120005764206
